| AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer PA Jänne, JCH Yang, DW Kim, D Planchard, Y Ohe, SS Ramalingam, ... New England Journal of Medicine 372 (18), 1689-1699, 2015 | 2272 | 2015 |
| In vitro models for the prediction of in vivo performance of oral dosage forms ES Kostewicz, B Abrahamsson, M Brewster, J Brouwers, J Butler, ... European Journal of Pharmaceutical Sciences 57, 342-366, 2014 | 398 | 2014 |
| The effects of pharmaceutical excipients on drug disposition TR Buggins, PA Dickinson, G Taylor Advanced drug delivery reviews 59 (15), 1482-1503, 2007 | 170 | 2007 |
| Clinical relevance of dissolution testing in quality by design PA Dickinson, WW Lee, PW Stott, AI Townsend, JP Smart, P Ghahramani, ... The AAPS journal 10, 380-390, 2008 | 168 | 2008 |
| Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies D Planchard, KH Brown, DW Kim, SW Kim, Y Ohe, E Felip, P Leese, ... Cancer Chemotherapy and pharmacology 77, 767-776, 2016 | 131 | 2016 |
| An investigation into the utility of a multi-compartmental, dynamic, system of the upper gastrointestinal tract to support formulation development and establish bioequivalence … PA Dickinson, R Abu Rmaileh, L Ashworth, RA Barker, WM Burke, ... The AAPS journal 14 (2), 196-205, 2012 | 122 | 2012 |
| Oral bioavailability of cinnarizine in dogs: relation to SNEDDS droplet size, drug solubility and in vitro precipitation AT Larsen, AG Ohlsson, B Polentarutti, RA Barker, AR Phillips, ... European Journal of Pharmaceutical Sciences 48 (1-2), 339-350, 2013 | 112 | 2013 |
| Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor PA Dickinson, MV Cantarini, J Collier, P Frewer, S Martin, K Pickup, ... Drug Metabolism and Disposition 44 (8), 1201-1212, 2016 | 106 | 2016 |
| The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance A Selen, PA Dickinson, A Müllertz, JR Crison, HB Mistry, MT Cruañes, ... Journal of Pharmaceutical Sciences 103 (11), 3377-3397, 2014 | 72 | 2014 |
| An investigation of the disintegration of tablets in biorelevant media S Anwar, JT Fell, PA Dickinson International journal of pharmaceutics 290 (1-2), 121-127, 2005 | 67 | 2005 |
| The inhibition of phagocytosis of respirable microspheres by alveolar and peritoneal macrophages BG Jones, PA Dickinson, M Gumbleton, IW Kellaway International journal of pharmaceutics 236 (1-2), 65-79, 2002 | 67 | 2002 |
| Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors E Bergman, P Forsell, EM Persson, L Knutson, P Dickinson, R Smith, ... International journal of pharmaceutics 341 (1-2), 134-142, 2007 | 65 | 2007 |
| Novel nanoparticles for pulmonary drug administration PA Dickinson, SW Howells, IW Kellaway Journal of drug targeting 9 (4), 295-302, 2001 | 63 | 2001 |
| Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans HA Thörn, A Lundahl, JA Schrickx, PA Dickinson, H Lennernäs European journal of pharmaceutical sciences 43 (3), 89-98, 2011 | 62 | 2011 |
| AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - Results of two parallel first-in-human Phase I studies. A Omlin, RJ Jones, R van der Noll, T Satoh, M Niwakawa, SA Smith, ... Investigational New Drugs. 33 (3), 679-690., 2015 | 55 | 2015 |
| The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib K Vishwanathan, PA Dickinson, K So, K Thomas, YM Chen, ... British journal of clinical pharmacology 84 (6), 1156-1169, 2018 | 51 | 2018 |
| The effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non‐small‐cell lung cancer and in healthy volunteers K Vishwanathan, PA Dickinson, K Bui, PA Cassier, A Greystoke, E Lisbon, ... The Journal of Clinical Pharmacology 58 (4), 474-484, 2018 | 48 | 2018 |
| Particulate composition PA Dickinson, IW Kellaway, SW Howells US Patent 7,018,657, 2006 | 48 | 2006 |
| Lung surfactant phospholipids inhibit the uptake of respirable microspheres by the alveolar macrophage NR8383 BG Jones, PA Dickinson, M Gumbleton, IW Kellaway Journal of pharmacy and pharmacology 54 (8), 1065-1072, 2002 | 45 | 2002 |
| An investigation of the solubility of various compounds in the hydrofluoroalkane propellants and possible model liquid propellants PA Dickinson, PC Seville, H McHale, NC Perkins, G Taylor Journal of aerosol medicine 13 (3), 179-186, 2000 | 43 | 2000 |
Anette MullertzBioneer:FARMA, Department of Pharmacy, University of CopenhagenVerifierad e-postadress på sund.ku.dk
